Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05265715
Other study ID # 202201100
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 14, 2022
Est. completion date March 22, 2024

Study information

Verified date March 2024
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The scientific premise for this study is the known impact of overweight/obesity on breast cancer risk and outcomes, the association between advanced glycation end-products (AGE) and high fat, highly processed foods common in Western diets, and the preclinical evidence suggesting a link between AGE and breast cancer independent of weight. The association between dietary and serum AGE in breast cancer survivors and prognosis has not been previously evaluated. However, preclinical studies suggest that AGE may represent a novel, lifestyle-linked, modifiable, prognostic biomarker, which could be targeted through lifestyle (diet and exercise) and/or pharmaceutical interventions to improve breast cancer prognosis. The proposed study will pave the way for a large scale randomized controlled trial to evaluate the impact of a low AGE diet on weight (BMI), known (IL-6 and CRP) and novel (AGE and RAGE) prognostic biomarkers, and ultimately on breast cancer prognosis.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date March 22, 2024
Est. primary completion date March 22, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of breast cancer, any subtype, stage I-III, within the last 36 months, who have completed primary therapy of their breast cancer (surgery, radiation, and chemotherapy). Must be at least 4 weeks post their last chemotherapy or radiation therapy. Concurrent hormonal therapy is allowed. - At least 18 years of age. - Determined to have a high AGE diet at baseline (dietary AGE intake greater than 14 Eq/day as assessed by food frequency questionnaire). - Ability to understand and willingness to sign an IRB approved written informed consent document. Exclusion Criteria: - Diagnosis of diabetes. - History of eating disorder or body dysmorphic disorder. - Active tobacco use (tobacco is a source of advanced glycation end products). - Active participation in other dietary or physical activity clinical trials or community interventions. - Taking and unwilling/unable to stop taking B-6 (pyridoxamine), B1 (thiamine) or metformin (all known AGE inhibitors).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Low AGE diet
The recommended daily AGE intake will be either: 7,500 kilounits [ku], which is a 50% reduction from the average 15,000 ku consumed by most adults or a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)
Procedure:
Research blood draw
Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)

Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine American Cancer Society, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility as measured by adherence rate Feasibility is a defined adherence rate of at least 80% of participants enrolled
Diet adherence will be categorized by the study dietitian at the end of the study and before the results of AGEs in serum or any analysis of outcomes to avoid bias. Following each phone session with the participants, the dietitian will elicit answers to the following question: since the last call did the participant use any cooking methods they were advised to avoid for certain food items? (yes/no).
The information will be used to calculate an adherence score. Adherence score is % phone calls of patient's report for full maintaining instructions to reduce AGEs.
Very high adherence= =80%; good adherence= 60-80%; partial adherence= 40-60%; lack of adherence but intention to adhere more in the future= =40%; lack of adherence and no intention to adhere more= =40%
At study completion for all enrolled participants (estimated to be 15 months)
Primary Feasibility as measured by dropout rate -Feasibility is defined as a dropout rate of less than 20% of participants enrolled At study completion for all enrolled participants (estimated to be 15 months)
Secondary Change in dietary AGE -Dietary AGE is estimated based on analysis of the 3 day food record patients will complete at baseline and study completion. A specific dietary AGE value will be assigned to each item on the 3 day food recall by consultant and dietary AGE expert Jaime Uribarri, MD. This value is based on his published dietary AGE database which accounts for type of food, portion size and cooking methods. At baseline and study completion (24 weeks)
Secondary Change in serum AGE Blood specimens for serum AGE analysis will be shipped from the University of San Diego Biorepository to the Medical University of South Carolina to be analyzed in the lab of study team member and expert AGE analyst, Dr. David Turner.
AGE (measured by the AGE metabolite carboxymethyllysine (ug/ml)) will be assessed in serum using commercially available 96-well format ELISA's and ROS detection kits (Cell Biolabs). Ne-carboxymethyllysine (CML) is an AGE metabolite extensively studied in animal models of disease and with regard to food content.
Baseline, week 12, and week 24
Secondary Correlation between serum AGE levels and BMI -The relationship between serum AGE levels and BMI will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between serum AGE levels and serum CRP -The relationship between serum AGE levels and serum CRP will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between serum AGE levels and IL6 -The relationship between serum AGE levels and IL6 will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between serum AGE levels and glucose -The relationship between serum AGE levels and glucose will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between serum AGE levels and leptin -The relationship between serum AGE levels and leptin will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between serum AGE levels and adiponectin -The relationship between serum AGE levels and adiponectin will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between dietary AGE and BMI -The relationship between dietary AGE and BMI will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between dietary AGE and serum CRP -The relationship between dietary AGE and serum CRP will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between dietary AGE and IL6 -The relationship between dietary AGE and IL6 will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between dietary AGE and insulin -The relationship between dietary AGE and insulin will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between dietary AGE and glucose -The relationship between dietary AGE and glucose will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between dietary AGE and leptin -The relationship between dietary AGE and leptin will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
Secondary Correlation between dietary AGE and adiponectin -The relationship between dietary AGE and adiponectin will be assessed using rank based correlation. Baseline, 12 weeks, and 24 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A